JP2007503849A - リン酸三カルシウム、その複合体、それらを組み入れたインプラント、及びそれらの製造方法 - Google Patents
リン酸三カルシウム、その複合体、それらを組み入れたインプラント、及びそれらの製造方法 Download PDFInfo
- Publication number
- JP2007503849A JP2007503849A JP2006522565A JP2006522565A JP2007503849A JP 2007503849 A JP2007503849 A JP 2007503849A JP 2006522565 A JP2006522565 A JP 2006522565A JP 2006522565 A JP2006522565 A JP 2006522565A JP 2007503849 A JP2007503849 A JP 2007503849A
- Authority
- JP
- Japan
- Prior art keywords
- tcp
- article
- additive
- less
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 443
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 332
- 229910000391 tricalcium phosphate Inorganic materials 0.000 title claims abstract description 313
- 235000019731 tricalcium phosphate Nutrition 0.000 title claims abstract description 313
- 229940078499 tricalcium phosphate Drugs 0.000 title claims abstract description 313
- 239000007943 implant Substances 0.000 title claims abstract description 57
- -1 complex thereof Substances 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000013078 crystal Substances 0.000 claims abstract description 101
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 62
- 239000002245 particle Substances 0.000 claims description 84
- 239000000654 additive Substances 0.000 claims description 74
- 230000000996 additive effect Effects 0.000 claims description 51
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 32
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 31
- 229920000642 polymer Polymers 0.000 claims description 26
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 20
- 239000011148 porous material Substances 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000000975 bioactive effect Effects 0.000 claims description 10
- 229920000954 Polyglycolide Polymers 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 239000004633 polyglycolic acid Substances 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical group [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000000399 orthopedic effect Effects 0.000 claims description 6
- 238000013001 point bending Methods 0.000 claims description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000000693 micelle Substances 0.000 claims description 5
- 239000002159 nanocrystal Substances 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 229920001299 polypropylene fumarate Polymers 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229910044991 metal oxide Inorganic materials 0.000 claims description 4
- 150000004706 metal oxides Chemical class 0.000 claims description 4
- 239000006259 organic additive Substances 0.000 claims description 4
- 239000004631 polybutylene succinate Substances 0.000 claims description 4
- 229920002961 polybutylene succinate Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940124346 antiarthritic agent Drugs 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical class N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 239000004053 dental implant Substances 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 239000003106 tissue adhesive Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 abstract description 125
- 230000015572 biosynthetic process Effects 0.000 abstract description 33
- 239000002244 precipitate Substances 0.000 abstract description 22
- 238000000576 coating method Methods 0.000 abstract description 21
- 238000006243 chemical reaction Methods 0.000 abstract description 17
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 239000000843 powder Substances 0.000 description 93
- 239000000463 material Substances 0.000 description 84
- 238000005245 sintering Methods 0.000 description 61
- 239000000243 solution Substances 0.000 description 52
- 239000012071 phase Substances 0.000 description 51
- 238000010304 firing Methods 0.000 description 43
- 239000011575 calcium Substances 0.000 description 41
- 239000002131 composite material Substances 0.000 description 37
- 229910019142 PO4 Inorganic materials 0.000 description 36
- 230000032683 aging Effects 0.000 description 36
- 229910052791 calcium Inorganic materials 0.000 description 36
- 235000021317 phosphate Nutrition 0.000 description 36
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 34
- 239000010452 phosphate Substances 0.000 description 33
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 31
- 229910000389 calcium phosphate Inorganic materials 0.000 description 19
- 235000011010 calcium phosphates Nutrition 0.000 description 19
- 238000009826 distribution Methods 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 239000003462 bioceramic Substances 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000001272 pressureless sintering Methods 0.000 description 15
- 238000002791 soaking Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000000919 ceramic Substances 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- 238000000280 densification Methods 0.000 description 11
- 238000001513 hot isostatic pressing Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 10
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 238000005452 bending Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 8
- 239000004568 cement Substances 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 159000000007 calcium salts Chemical class 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 229910052586 apatite Inorganic materials 0.000 description 6
- 230000002051 biphasic effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002114 nanocomposite Substances 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 239000003495 polar organic solvent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 238000007731 hot pressing Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003754 machining Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000004254 Ammonium phosphate Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 4
- 235000019289 ammonium phosphates Nutrition 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000001354 calcination Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 3
- 239000001639 calcium acetate Substances 0.000 description 3
- 235000011092 calcium acetate Nutrition 0.000 description 3
- 229960005147 calcium acetate Drugs 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000009694 cold isostatic pressing Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 229910000392 octacalcium phosphate Inorganic materials 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 description 3
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- FJTUUPVRIANHEX-UHFFFAOYSA-N butan-1-ol;phosphoric acid Chemical compound CCCCO.OP(O)(O)=O FJTUUPVRIANHEX-UHFFFAOYSA-N 0.000 description 2
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000009388 chemical precipitation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
- 238000003826 uniaxial pressing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000007704 wet chemistry method Methods 0.000 description 2
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical class CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229910001316 Ag alloy Inorganic materials 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZUQAPLKKNAQJAU-UHFFFAOYSA-N acetylenediol Chemical compound OC#CO ZUQAPLKKNAQJAU-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229920005550 ammonium lignosulfonate Polymers 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- WPKYZIPODULRBM-UHFFFAOYSA-N azane;prop-2-enoic acid Chemical compound N.OC(=O)C=C WPKYZIPODULRBM-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000005234 chemical deposition Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007656 fracture toughness test Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000002241 glass-ceramic Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000002707 nanocrystalline material Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001523 phosphate polymer Polymers 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 238000007569 slipcasting Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- RUQIYMSRQQCKIK-UHFFFAOYSA-M sodium;2,3-di(propan-2-yl)naphthalene-1-sulfonate Chemical compound [Na+].C1=CC=C2C(S([O-])(=O)=O)=C(C(C)C)C(C(C)C)=CC2=C1 RUQIYMSRQQCKIK-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002993 sponge (artificial) Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- XTTGYFREQJCEML-UHFFFAOYSA-N tributyl phosphite Chemical compound CCCCOP(OCCCC)OCCCC XTTGYFREQJCEML-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/60—Compounds characterised by their crystallite size
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/10—Solid density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/60—Optical properties, e.g. expressed in CIELAB-values
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
- Prostheses (AREA)
- Compositions Of Oxide Ceramics (AREA)
Abstract
【選択図】なし
Description
本発明は、概してバイオセラミック、特にリン酸三カルシウムバイオセラミック、これらの材料を組み入れた複合体、及びそれらの製造方法に関する。
許容可能な期間にわたるオステオインテグレーションを提供しつつ多様な臨床適用用の優れた構造支持体を提供するインプラント材料の必要性が広く認識されている。従来の金属インプラントは、短期の機械的目的を達成する埋め込んだ領域の機械的安定性を保証するように設計されるが、皮膚上への隆起、不均一な治癒、骨萎縮、インプラントの移動及びゆるみを含む、多数の長期的な臨床的問題を生じ、これらすべてはインプラントを取り除く二度目の手術をもたらしうる。
本発明は、特に小さな結晶径及び/又は粒子径を有するリン酸三カルシウム(TCP)材料を含む組成物及び物品を提供する。本発明はさらに、完全に高密度で無欠陥であるか又は広範囲な多孔度を有する、多様な物品へとTCPを統合する方法を提供する。
本発明はナノ構造化TCPの合成法、埋め込み可能な物品中へのナノ構造化TCPの処理、及び関連する方法を実施する工程を提供する。望ましくは、これらの方法は、(a)微細構造制御及びナノメートルスケールでの設計、(b)分子レベルでの相均一性及び化学的均質性、(c)化学的及び物理学的特性の均一性、(d)部分的に強化されたリン酸三カルシウムの機械加工性、(e)焼結挙動、(f)機械的信頼性及び強度、(g)ネットシェイプ成形、(h)多孔質体及び高密度体の製造、(i)複合体材料の形成、及び/又は(j)遺伝子、薬物及びタンパク質の輸送デバイスに関する1つ以上の改良をもたらす。
焼結のためのナノ結晶TCP合成の最適化
最適条件の決定−前駆濃度の影響
最適条件の決定−添加速度の影響
最適条件の決定−pHの影響
最適条件の決定−エージング時間の影響
最適条件の決定−エージング温度の影響
ナノ結晶TCPは、化学的析出、その後、焼結により合成することができる。前駆濃度、pH、添加速度、エージング時間、エージング温度、及び焼成温度の、晶子径、化学量論、粒子の径と分布、形態、結晶化度及び構造的成長への影響を調べることができる。重要な処理パラメーター及びこれらをそれにより制御可能な方法を特定することによって、バルクTCPの機械的特性を向上するために、晶子径と処理に関連する欠陥構造を減らすことができる。さらに、集積を減らし、粒子の形態と径分布を制御し、粒子の化学的反応性を制御するパラメーターを使用して、より低い焼結温度において完全な高密度化を達成することができる。焼成されたナノTCP粉末のXRDパターンは、β−TCPファイル(JC−PDS 9−169)とよく一致する。そのピークはTCPのナノ結晶性のため、かなりブロードである。
焼成温度に対する合成条件の影響
TCP形成に必要とされる焼成温度に対する前駆体及び溶媒環境の影響
TCP粉末の無加圧焼結
TCP粉末のホットプレス
TCP粉末のネットシェイプ成形及び熱間等方圧加圧
TCPの吸収及び生体活性
TCPナノ複合体
リン酸カルシウム−ポリマーナノ複合体
多孔性TCPの処理
両連続二相リン酸カルシウム複合体
プラスミドDNA、RNA、タンパク質、及び薬剤の輸送ビヒクルとしてのリン酸カルシウム構造
Claims (68)
- 約5μm以下の平均粒径、約250nm以下の平均結晶径、及び約20m2/g以上の表面積を有する粒子状リン酸三カルシウム(TCP)を含む組成物。
- 粒子状TCPが約1μm以下の平均粒子径を有する、請求項1に記載の組成物。
- 粒子状TCPが約200nm以下の平均結晶径を有する、請求項1に記載の組成物。
- 粒子状TCPがα−TCP、β−TCP、又はこれらの組み合わせを含む、請求項1に記載の組成物。
- 粒子状リン酸三カルシウムが高密度化されている、請求項1に記載の組成物。
- 補助添加物をさらに含む、請求項1に記載の組成物。
- 補助添加物が約1容量%〜約50容量%の量で存在する、請求項6に記載の組成物。
- 補助添加物が構造添加物を含む、請求項6に記載の組成物。
- 構造添加物が金属酸化物を含む、請求項8に記載の組成物。
- 金属酸化物がジルコニアを含む、請求項9に記載の組成物。
- 構造添加物が約2以上のアスペクト比を有する、請求項8に記載の組成物。
- 補助添加物が有機種である、請求項6に記載の組成物。
- 補助添加物が高分子添加物である、請求項6に記載の組成物。
- 高分子添加物が、ポリ乳酸、ポリグリコール酸、ポリ乳酸/ポリグリコール酸共重合体、ポリプロピレンフマレート、ポリヒドロキシ酪酸、ポリヒドロキシ吉草酸、ポリカプロラクトン、ポリヒドロキシカルボン酸、ポリブチレンスクシネート、ポリブチレンアジペート、コラーゲン、キトサン、アルギネート、セルロース、スターチ、糖、ポリペプチド、ポリエチレングリコール、ビニルピロリドン、アクリルアミド、メタクリレート、共重合ミセル、及びこれらの組み合わせからなる群から選ばれる、請求項13に記載の組成物。
- 補助添加物が生物学的添加物である、請求項6に記載の組成物。
- 生物学的添加物が、プラスミドDNA、RNA、タンパク質、骨形成タンパク質、及びこれらの組み合わせからなる群から選ばれる、請求項15に記載の組成物。
- 補助添加物が薬学的添加物である、請求項6に記載の組成物。
- 約80μm以下の平均結晶径、理論密度約90%以上の密度を有する強化TCP構造を含む物品。
- 約95%以上の密度を有する、請求項18に記載の物品。
- 約10%以下の空隙容量を有する、請求項18に記載の物品。
- TCP構造が約10μm以下の平均結晶径を有する、請求項18に記載の物品。
- TCP構造が約1μm以下の平均結晶径を有する、請求項21に記載の物品。
- TCP構造が約500nm以下の平均結晶径を有する、請求項22に記載の物品。
- TCP構造が約100MPa以上の3点曲げ強さを有する、請求項18に記載の物品。
- TCP構造が約200MPa以上の3点曲げ強さを有する、請求項24に記載の物品。
- TCP構造がα-TCP、β-TCP、又はこれらの組み合わせを含む、請求項18に記載の物品。
- 少なくとも約0.5cmの寸法を有する、請求項18に記載の物品。
- 人工器官である、請求項18に記載の物品。
- 人工器官の少なくとも一部である、請求項18に記載の物品。
- 人工器官の外部被覆を含む、請求項18に記載の物品。
- 生体活性インプラントである、請求項18に記載の物品。
- 生体活性インプラントが整形外科的又は歯科的インプラントである、請求項31に記載の物品。
- アパタイト構造が補助添加物を含む、請求項18に記載の物品。
- 補助添加物が構造添加物を含む、請求項33に記載の物品。
- 構造添加物が金属酸化物を含む、請求項34に記載の物品。
- 補助添加物がナノ結晶である、請求項33に記載の物品。
- 補助添加物が金属又は合金である、請求項33に記載の物品。
- 補助添加物が約1容量%〜約50容量%の間の量で加えられている、請求項33に記載の物品。
- 約1μm以下の平均結晶径及び約20%以上の多孔度を有する強化TCP構造を含む物品。
- TCP構造が約40%以上の多孔度を有する、請求項39に記載の物品。
- TCP構造が約300μm以下の平均孔径を有する、請求項39に記載の物品。
- TCP構造が約100MPa以上の圧縮強さを有する、請求項39に記載の物品。
- TCP構造が約250nm以下の平均結晶径を有する、請求項39に記載の物品。
- TCP構造がα-TCP、β-TCP、又はこれらの組み合わせを含む、請求項39に記載の物品。
- 少なくとも約0.5cmの寸法を有する、請求項39に記載の物品。
- 人工器官である、請求項39に記載の物品。
- 人工器官の少なくとも一部である、請求項39に記載の物品。
- 人工器官の外部被覆を含む、請求項39に記載の物品。
- 生体活性インプラントである、請求項39に記載の物品。
- 生体活性インプラントが整形外科的又は歯科的インプラントである、請求項49に記載の物品。
- アパタイト構造が補助添加物を含む、請求項39に記載の物品。
- 補助添加物が有機添加物である、請求項51に記載の物品。
- 補助添加物が高分子添加物である、請求項51に記載の物品。
- 高分子添加物が、ポリ乳酸、ポリグリコール酸、ポリ乳酸/ポリグリコール酸共重合体、ポリプロピレンフマレート、ポリヒドロキシ酪酸、ポリヒドロキシ吉草酸、ポリカプロラクトン、ポリヒドロキシカルボン酸、ポリブチレンスクシネート、ポリブチレンアジペート、コラーゲン、キトサン、アルギネート、セルロース、スターチ、糖、ポリペプチド、ポリエチレングリコール、ビニルピロリドン、アクリルアミド、メタクリレート、共重合ミセル、及びこれらの組み合わせからなる群から選ばれる、請求項53に記載の物品。
- 補助添加物が生物学的添加物である、請求項51に記載の物品。
- 生物学的添加物が、プラスミドDNA、RNA、タンパク質、骨形成タンパク質、及びそれらの組み合わせからなる群から選ばれる、請求項55に記載の物品。
- 補助添加物が薬学的添加物である、請求項51に記載の物品。
- 薬学的添加物が、ビスフォスフォネート、シスプラチン化合物、抗生物質、抗炎症剤、抗関節病体質剤、エリスロポエチン、及びこれらの組み合わせからなる群から選ばれる、請求項57に記載の物品。
- 補助添加物がハイドロキシアパタイトである、請求項51に記載の物品。
- 補助添加物が約1容量%〜約50容量%の間の量で加えられている、請求項51に記載の物品。
- 約7μm以下の平均結晶径、理論密度約90%以上の密度、及び約100MPa以上の3点曲げ強さを有するTCPを含むインプラント。
- α-TCP、β-TCP、又はこれらの組み合わせを含む、請求項61に記載のインプラント。
- 脊椎インプラントである、請求項61に記載のインプラント。
- 歯科的インプラントである、請求項61に記載のインプラント。
- 内部又は外部固定インプラントである、請求項61に記載のインプラント。
- 軟組織接着用インプラントである、請求項61に記載のインプラント。
- 約3ヶ月以上の吸収時間を有する、請求項61に記載のインプラント。
- 約1年以上の吸収時間を有する、請求項67に記載のインプラント。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/635,402 US8029755B2 (en) | 2003-08-06 | 2003-08-06 | Tricalcium phosphates, their composites, implants incorporating them, and method for their production |
| PCT/US2004/022304 WO2005032456A2 (en) | 2003-08-06 | 2004-08-03 | Tricalcium phosphates, their composites, implants incorporating them, and methods for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007503849A true JP2007503849A (ja) | 2007-03-01 |
Family
ID=34116237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522565A Pending JP2007503849A (ja) | 2003-08-06 | 2004-08-03 | リン酸三カルシウム、その複合体、それらを組み入れたインプラント、及びそれらの製造方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8029755B2 (ja) |
| EP (1) | EP1660036A4 (ja) |
| JP (1) | JP2007503849A (ja) |
| AU (1) | AU2004277375B2 (ja) |
| CA (1) | CA2535085A1 (ja) |
| WO (1) | WO2005032456A2 (ja) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006167469A (ja) * | 2004-12-15 | 2006-06-29 | Heraeus Kulzer Gmbh | 作用物質を遅延放出する、単数の抗生物質/複数の抗生物質を含有する骨代用材料 |
| JP2009513197A (ja) * | 2005-10-27 | 2009-04-02 | トーメン メディカル アーゲー | 歯科インプラント及びその製造方法 |
| JP2009526614A (ja) * | 2006-02-17 | 2009-07-23 | バイオメト マニファクチャリング コーポレイション | 多孔性金属インプラントの形成方法および形成装置 |
| JP2010284522A (ja) * | 2009-06-12 | 2010-12-24 | Kaohsiung Medical Univ | リン酸カルシウム骨セメント、その前駆体およびその作製方法 |
| JP2011250868A (ja) * | 2010-05-31 | 2011-12-15 | Chiba Inst Of Technology | リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 |
| US8115587B2 (en) | 2008-03-28 | 2012-02-14 | Murata Manufacturing Co., Ltd. | NTC thermistor ceramic, method for producing NTC thermistor ceramic, and NTC thermistor |
| JP2012030993A (ja) * | 2010-07-29 | 2012-02-16 | National Institute Of Advanced Industrial Science & Technology | 液相レーザー法を利用したリン酸カルシウム成膜方法 |
| JP2015509018A (ja) * | 2012-01-19 | 2015-03-26 | デピュー インターナショナル リミテッド | 骨充填剤組成物 |
| JP2016166125A (ja) * | 2015-02-27 | 2016-09-15 | 国立大学法人東北大学 | リン酸カルシウム合成装置及び合成方法 |
| KR20180024176A (ko) * | 2016-08-29 | 2018-03-08 | 주식회사 행남생활건강 | 투광성 도자기 조성물 및 이의 제조방법 |
| JP2018528005A (ja) * | 2015-09-14 | 2018-09-27 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ (ウ・ペ・エフ・エル)Ecole Polytechnique Federale De Lausanne (Epfl) | 骨再生のための組成物 |
| JP2018531210A (ja) * | 2015-09-25 | 2018-10-25 | クリーン ワールド テクノロジーズ リミテッドClean World Technologies Ltd. | リン酸カルシウム組成物を生産すること |
| WO2019069825A1 (ja) * | 2017-10-05 | 2019-04-11 | 国立研究開発法人産業技術総合研究所 | β-TCP基材とOCP結晶層を含む複合体及びその製造方法 |
| JPWO2021161987A1 (ja) * | 2020-02-12 | 2021-08-19 | ||
| JP2022545185A (ja) * | 2019-08-20 | 2022-10-26 | セラダプティブ インク | 骨インプラントにおける係留可能なタンパク質の送達のための材料 |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8123814B2 (en) * | 2001-02-23 | 2012-02-28 | Biomet Manufacturing Corp. | Method and appartus for acetabular reconstruction |
| US7597715B2 (en) * | 2005-04-21 | 2009-10-06 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| US8029755B2 (en) * | 2003-08-06 | 2011-10-04 | Angstrom Medica | Tricalcium phosphates, their composites, implants incorporating them, and method for their production |
| US8529625B2 (en) | 2003-08-22 | 2013-09-10 | Smith & Nephew, Inc. | Tissue repair and replacement |
| JP4699902B2 (ja) * | 2003-10-27 | 2011-06-15 | Hoya株式会社 | リン酸カルシウムセラミックス多孔体及びその製造方法 |
| KR100583849B1 (ko) * | 2004-01-20 | 2006-05-26 | 재단법인서울대학교산학협력재단 | 인산칼슘 화합물의 폴리메릭 졸 제조방법 |
| SE527610C2 (sv) * | 2004-06-15 | 2006-04-25 | Promimic Ab | Förfarande för framställning av syntetiskt, kristallint kalciumfosfat i nanostorlek |
| US9078884B2 (en) | 2004-09-21 | 2015-07-14 | Thomas Joseph Lally | Bio-material composition and method for spinal fusion |
| WO2006034420A2 (en) * | 2004-09-21 | 2006-03-30 | Thomas Joseph Lally | Multi-purpose bio-material composition |
| US7879388B2 (en) * | 2004-10-28 | 2011-02-01 | The Regents Of The University Of Michigan | Methods for production and use of synthetic hydroxyapatite and fluorapatite nanorods, and superstructures assembled from the same |
| DE602005017067D1 (de) * | 2004-11-15 | 2009-11-19 | Unitika Ltd | Flammwidrige biologisch abbaubare polyesterharzzusammensetzung, herstellungsverfahren dafür und daraus erhaltener formkörper |
| US20060129215A1 (en) * | 2004-12-09 | 2006-06-15 | Helmus Michael N | Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery |
| US20080119859A1 (en) * | 2005-01-12 | 2008-05-22 | Lally Thomas J | Multi-Purpose Bio-Material Composition |
| US8066778B2 (en) * | 2005-04-21 | 2011-11-29 | Biomet Manufacturing Corp. | Porous metal cup with cobalt bearing surface |
| US8292967B2 (en) * | 2005-04-21 | 2012-10-23 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US8021432B2 (en) * | 2005-12-05 | 2011-09-20 | Biomet Manufacturing Corp. | Apparatus for use of porous implants |
| US8266780B2 (en) * | 2005-04-21 | 2012-09-18 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US8814567B2 (en) * | 2005-05-26 | 2014-08-26 | Zimmer Dental, Inc. | Dental implant prosthetic device with improved osseointegration and esthetic features |
| ES2265785A1 (es) * | 2005-07-26 | 2007-02-16 | Universidad De Santiago De Compostela | Procedimiento de obtencion de polvos finos de beta-fosfato tricalcico o sus mezclas a partir de precursores amorfos. |
| US20070026039A1 (en) * | 2005-07-29 | 2007-02-01 | Drumheller Paul D | Composite self-cohered web materials |
| EP1922052B1 (en) * | 2005-08-08 | 2010-11-03 | Angstrom Medica, Inc. | Cement products and methods of making and using the same |
| US8562346B2 (en) | 2005-08-30 | 2013-10-22 | Zimmer Dental, Inc. | Dental implant for a jaw with reduced bone volume and improved osseointegration features |
| CA2620427C (en) | 2005-08-30 | 2014-03-11 | Zimmer Dental, Inc. | Dental implant with improved osseointegration features |
| BRPI0617086B8 (pt) | 2005-09-09 | 2021-06-22 | Agnovos Healtcare Llc | cimento composto substituto de enxerto ósseo e artigos dele originados |
| WO2007030752A2 (en) * | 2005-09-09 | 2007-03-15 | University Of Arkansas At Little Rock | System and method for tissue generation and bone regeneration |
| US9763788B2 (en) | 2005-09-09 | 2017-09-19 | Board Of Trustees Of The University Of Arkansas | Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same |
| US8025903B2 (en) | 2005-09-09 | 2011-09-27 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
| US8936805B2 (en) | 2005-09-09 | 2015-01-20 | Board Of Trustees Of The University Of Arkansas | Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same |
| CA2626347A1 (en) * | 2005-10-19 | 2007-04-26 | A Enterprises, Inc. | Curable bone substitute |
| AU2006315629B2 (en) * | 2005-11-14 | 2012-04-19 | Biomet 3I, Llc | Deposition of discrete nanoparticles on an implant surface |
| DE102005060203B4 (de) * | 2005-12-14 | 2009-11-12 | Gkss-Forschungszentrum Geesthacht Gmbh | Biokompatibler Magnesiumwerkstoff, Verfahren zu seiner Herstellung und seiner Verwendung |
| EP1976460A4 (en) | 2006-01-19 | 2012-06-20 | Warsaw Orthopedic Inc | INJECTABLE AND FORMABLE BONE REPLACEMENT MATERIALS |
| JP2007222611A (ja) * | 2006-01-26 | 2007-09-06 | National Institute Of Advanced Industrial & Technology | 薬剤徐放性人工骨及びその製造方法 |
| WO2007089894A2 (en) * | 2006-01-31 | 2007-08-09 | Indiana University Research & Technology Corporation | Materials and methods for manufacturing amorphous tricalcium phosphate and metal oxide alloys of amorphous tricalcium phosphate and methods of using the same |
| WO2007094672A1 (en) * | 2006-02-17 | 2007-08-23 | Progentix Orthobiology B.V. | Osteoinductive calcium phosphates |
| US7507286B2 (en) * | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
| WO2008140551A2 (en) | 2006-10-16 | 2008-11-20 | Pioneer Surgical Technology, Inc. | Fusion device |
| US7972648B2 (en) * | 2006-10-24 | 2011-07-05 | Biomet 3I, Llc | Deposition of discrete nanoparticles on a nanostructured surface of an implant |
| US20130150943A1 (en) | 2007-01-19 | 2013-06-13 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
| US8814930B2 (en) | 2007-01-19 | 2014-08-26 | Elixir Medical Corporation | Biodegradable endoprosthesis and methods for their fabrication |
| US8182890B2 (en) * | 2007-01-19 | 2012-05-22 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
| ES2968634T3 (es) * | 2007-02-06 | 2024-05-13 | Pioneer Surgical Tech Inc | Dispositivos de implante intervertebral |
| US20090010990A1 (en) * | 2007-06-20 | 2009-01-08 | Little Marisa A | Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process |
| JP2010533563A (ja) | 2007-07-19 | 2010-10-28 | ボストン サイエンティフィック リミテッド | 吸着抑制表面を有する内部人工器官 |
| WO2009020520A1 (en) | 2007-08-03 | 2009-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
| US20090061389A1 (en) * | 2007-08-30 | 2009-03-05 | Matthew Lomicka | Dental implant prosthetic device with improved osseointegration and shape for resisting rotation |
| CN101842062B (zh) * | 2007-09-25 | 2013-04-03 | 拜欧米特制造公司 | 非骨水泥型胫骨托的制造方法 |
| JP5806466B2 (ja) | 2008-01-28 | 2015-11-10 | バイオメット・3アイ・エルエルシー | 親水性を向上させたインプラント表面 |
| GB0805052D0 (en) * | 2008-03-19 | 2008-04-16 | 3M Innovative Properties Co | A method for making a dental blank, a press and a system for making dental blanks |
| EP2273952B1 (en) * | 2008-04-02 | 2018-02-21 | Pioneer Surgical Technology, Inc. | Intervertebral implant devices for supporting vertebrae and devices for insertion thereof |
| ES2423504T3 (es) | 2008-04-22 | 2013-09-20 | Boston Scientific Scimed, Inc. | Dispositivos médicos que tienen un recubrimiento de material inorgánico |
| WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
| US9095396B2 (en) | 2008-07-02 | 2015-08-04 | Zimmer Dental, Inc. | Porous implant with non-porous threads |
| US8562348B2 (en) | 2008-07-02 | 2013-10-22 | Zimmer Dental, Inc. | Modular implant with secured porous portion |
| US8899982B2 (en) | 2008-07-02 | 2014-12-02 | Zimmer Dental, Inc. | Implant with structure for securing a porous portion |
| US8906111B2 (en) * | 2008-07-02 | 2014-12-09 | The University Of Tokyo | Artificial bone material having controlled calcium ion elution |
| US8231387B2 (en) | 2008-07-02 | 2012-07-31 | Zimmer, Inc. | Porous implant with non-porous threads |
| US8568696B2 (en) * | 2008-08-06 | 2013-10-29 | Indiana Nanotech Llc | Grinding method for the manipulation or preservation of calcium phosphate hybrid properties |
| US20100114314A1 (en) | 2008-11-06 | 2010-05-06 | Matthew Lomicka | Expandable bone implant |
| JP4392460B1 (ja) * | 2008-11-13 | 2010-01-06 | 株式会社カタリメディック | 芳香族炭化水素の残留量が低いリン酸カルシウム多孔体 |
| WO2010094813A1 (es) * | 2009-02-10 | 2010-08-26 | Azurebio, S. L. | Material de regeneración ósea a partir de combinaciones de monetita con otros compuestos de calcio bioactivos |
| US20100226956A1 (en) | 2009-03-06 | 2010-09-09 | Per Kjellin | Production of moldable bone substitute |
| US9707058B2 (en) | 2009-07-10 | 2017-07-18 | Zimmer Dental, Inc. | Patient-specific implants with improved osseointegration |
| US9074267B2 (en) * | 2009-07-22 | 2015-07-07 | The Hong Kong Polytechnic University | Rapid fabrication of porous metal-based biomaterial by microwave sintering |
| US20110046238A1 (en) * | 2009-08-24 | 2011-02-24 | Keiser Bruce A | Calcium based carrier particles |
| US20110046239A1 (en) * | 2009-08-24 | 2011-02-24 | Keiser Bruce A | Calcium based carrier particles |
| US8383033B2 (en) | 2009-10-08 | 2013-02-26 | Biomet Manufacturing Corp. | Method of bonding porous metal to metal substrates |
| US8602782B2 (en) | 2009-11-24 | 2013-12-10 | Zimmer Dental, Inc. | Porous implant device with improved core |
| US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| US8641418B2 (en) | 2010-03-29 | 2014-02-04 | Biomet 3I, Llc | Titanium nano-scale etching on an implant surface |
| EP2529764A1 (de) * | 2011-05-31 | 2012-12-05 | Curasan AG | Biologisch degradierbares kompositmaterial |
| WO2013028551A2 (en) | 2011-08-19 | 2013-02-28 | Pioneer Surigical Technology | Injectable fillers for aesthetic medical enhancement and for therapeutic applications |
| US9132021B2 (en) | 2011-10-07 | 2015-09-15 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
| ES2407131B2 (es) * | 2011-12-07 | 2013-11-15 | Universidad Rey Juan Carlos | Bloques sintéticos para uso en implantes dentales. |
| ES2559467T3 (es) | 2011-12-23 | 2016-02-12 | Pioneer Surgical Technology, Inc. | Matriz continua con partículas osteoconductoras dispersadas en la misma, procedimiento de formación, y su uso para regenerar el hueso con la misma |
| US9907657B2 (en) * | 2012-02-09 | 2018-03-06 | Arthrex, Inc. | Porous coating for orthopedic implant utilizing porous, shape memory materials |
| ES2671740T3 (es) | 2012-03-20 | 2018-06-08 | Biomet 3I, Llc | Superficie de tratamiento para una superficie de implante |
| PL221445B1 (pl) * | 2012-06-27 | 2016-04-29 | Inst Wysokich Ciśnień Polskiej Akademii Nauk | Sposób wytwarzania implantów kostnych |
| CN104507413B (zh) * | 2012-07-31 | 2016-04-27 | 可乐丽则武齿科株式会社 | 牙科用研磨坯料及其制造方法 |
| US9272072B1 (en) | 2012-10-19 | 2016-03-01 | Nuvasive, Inc. | Osteoinductive bone graft substitute |
| ES2751398T3 (es) * | 2013-01-15 | 2020-03-31 | Tepha Inc | Implantes para regeneración de tejido blando y tejido duro |
| NL2011195C2 (en) | 2013-07-18 | 2015-01-21 | Xpand Biotechnology B V | Method for producing an osteoinductive calcium phosphate and products thus obtained. |
| TWI651103B (zh) | 2013-12-13 | 2019-02-21 | 萊特醫技股份有限公司 | 多相骨移植替代材料 |
| CN106132534B (zh) * | 2014-03-31 | 2020-06-19 | 株式会社日本触媒 | 颗粒状吸水剂及其制造方法 |
| US9259339B1 (en) | 2014-08-15 | 2016-02-16 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US9855156B2 (en) * | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
| US11331191B2 (en) | 2015-08-12 | 2022-05-17 | Howmedica Osteonics Corp. | Bioactive soft tissue implant and methods of manufacture and use thereof |
| CA2938576A1 (en) * | 2015-08-12 | 2017-02-12 | Howmedica Osteonics Corp. | Methods for forming scaffolds |
| CN109561955B (zh) | 2016-05-16 | 2021-04-16 | 万能医药公司 | 撑开支架 |
| US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
| JP6746117B2 (ja) * | 2016-06-15 | 2020-08-26 | 株式会社小糸製作所 | アパタイト結晶の製造方法 |
| KR101908287B1 (ko) * | 2016-06-30 | 2018-10-15 | 한국전자통신연구원 | 다공성 골 이식재 및 이의 제조 방법 |
| CA3074834C (en) | 2017-09-08 | 2025-09-16 | Xtant Medical Holdings, Inc. | INTERVERTEBRAL IMPLANTS, INSTRUMENTS AND PROCESSES |
| USD907771S1 (en) | 2017-10-09 | 2021-01-12 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
| GB201802184D0 (en) * | 2018-02-09 | 2018-03-28 | Promimic Ab | Products and methods |
| CN110818403B (zh) * | 2018-08-09 | 2022-04-29 | 苏州鼎安科技有限公司 | 一种气氛保护常压烧结制备透明磷酸钙生物陶瓷的方法 |
| US20200102458A1 (en) * | 2018-09-28 | 2020-04-02 | Icl Specialty Products Inc. | Cool Roof Coating Containing Multifunctional Additive |
| US20230288173A1 (en) * | 2020-07-16 | 2023-09-14 | The Regents Of The University Of California | Composite structures for energy dissipation and method |
| LV15709A (lv) * | 2021-08-10 | 2023-02-20 | Rīgas Tehniskā Universitāte | Zāļu piegādes sistēmas uz amorfa kalcija fosfāta keramikas bāzes un tās iegūšanas paņēmiens |
| US12343444B2 (en) | 2021-08-16 | 2025-07-01 | Bone Solutions, Inc. | Structural implant to prevent bone defects |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0731673A (ja) * | 1993-07-19 | 1995-02-03 | Asahi Optical Co Ltd | 生体吸収性高分子含有硬化型骨補填材 |
| JP2001054564A (ja) * | 1999-08-17 | 2001-02-27 | Natl Inst For Res In Inorg Mater | 生体材料 |
| WO2003011343A1 (en) * | 2001-07-27 | 2003-02-13 | National Institute Of Advanced Industrial Science And Technology | Method of regenerating bone/chondral tissues by transferring transcriptional factor gene |
| WO2003030956A2 (en) * | 2001-10-12 | 2003-04-17 | Osteotech, Inc. | Improved bone graft |
| JP2003180814A (ja) * | 2001-12-18 | 2003-07-02 | Olympus Optical Co Ltd | スキャホールド |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6287406A (ja) * | 1985-10-11 | 1987-04-21 | Agency Of Ind Science & Technol | β−リン酸三カルシウムの製造方法 |
| JPH021285A (ja) * | 1988-01-11 | 1990-01-05 | Asahi Optical Co Ltd | 固着可能な歯科用及び医科用顆粒状骨補填材、その固着方法及び骨補填物 |
| US5185177A (en) * | 1988-02-08 | 1993-02-09 | Mitsubishi Kasei Corporation | Producing a ceramic implant by coating a powder mixture of zirconia and either tricalcium phosphate or hydroxyapatite on a molded unsintered body of partially stabilized zirconia and then sintering the article |
| US4880610A (en) | 1988-04-20 | 1989-11-14 | Norian Corporation | In situ calcium phosphate minerals--method and composition |
| US5322675A (en) | 1990-11-09 | 1994-06-21 | Director-General Of Agency Of Industrial Science And Technology | Method of preparing calcium phosphate |
| US5782971B1 (en) | 1991-06-28 | 1999-09-21 | Norian Corp | Calcium phosphate cements comprising amorophous calcium phosphate |
| US5658332A (en) | 1994-06-30 | 1997-08-19 | Orthovita, Inc. | Bioactive granules for bone tissue formation |
| US5569442A (en) | 1994-11-04 | 1996-10-29 | Norian Corporation | Reactive tricalcium phosphate compositions and uses |
| US6287341B1 (en) | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
| US6117456A (en) | 1995-05-19 | 2000-09-12 | Etex Corporation | Methods and products related to the physical conversion of reactive amorphous calcium phosphate |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US5783217A (en) | 1995-11-07 | 1998-07-21 | Etex Corporation | Low temperature calcium phosphate apatite and a method of its manufacture |
| US5681872A (en) | 1995-12-07 | 1997-10-28 | Orthovita, Inc. | Bioactive load bearing bone graft compositions |
| US5914356A (en) | 1996-12-06 | 1999-06-22 | Orthovita, Inc. | Bioactive load bearing bone bonding compositions |
| US6013591A (en) * | 1997-01-16 | 2000-01-11 | Massachusetts Institute Of Technology | Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production |
| US5939039A (en) | 1997-01-16 | 1999-08-17 | Orthovita, Inc. | Methods for production of calcium phosphate |
| JP3679570B2 (ja) | 1997-03-14 | 2005-08-03 | ペンタックス株式会社 | 骨補填材及びその製造方法 |
| DE69906441T2 (de) | 1998-09-15 | 2004-04-08 | Isotis B.V. | Beschichtungsverfahren von medizinischen Implantaten |
| US6569396B1 (en) | 1999-03-26 | 2003-05-27 | Nara Machinery Co., Ltd. | Method for producing calcium phosphate powder |
| US6458162B1 (en) | 1999-08-13 | 2002-10-01 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
| EP1121943B1 (en) * | 1999-08-17 | 2007-07-04 | Taki Chemical Co., Ltd. | Biological materials |
| DE19940717A1 (de) * | 1999-08-26 | 2001-03-01 | Gerontocare Gmbh | Resorblerbares Knochenersatz- und Knochenaufbaumaterial |
| US7045125B2 (en) | 2000-10-24 | 2006-05-16 | Vita Special Purpose Corporation | Biologically active composites and methods for their production and use |
| US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US6840961B2 (en) | 2001-12-21 | 2005-01-11 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| US8029755B2 (en) * | 2003-08-06 | 2011-10-04 | Angstrom Medica | Tricalcium phosphates, their composites, implants incorporating them, and method for their production |
-
2003
- 2003-08-06 US US10/635,402 patent/US8029755B2/en not_active Expired - Fee Related
-
2004
- 2004-08-03 AU AU2004277375A patent/AU2004277375B2/en not_active Ceased
- 2004-08-03 CA CA002535085A patent/CA2535085A1/en not_active Abandoned
- 2004-08-03 WO PCT/US2004/022304 patent/WO2005032456A2/en not_active Ceased
- 2004-08-03 JP JP2006522565A patent/JP2007503849A/ja active Pending
- 2004-08-03 EP EP04809488A patent/EP1660036A4/en not_active Withdrawn
-
2011
- 2011-09-08 US US13/228,216 patent/US8597604B2/en not_active Expired - Fee Related
-
2013
- 2013-11-01 US US14/070,122 patent/US9517293B2/en not_active Expired - Lifetime
-
2016
- 2016-11-07 US US15/345,155 patent/US10011486B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0731673A (ja) * | 1993-07-19 | 1995-02-03 | Asahi Optical Co Ltd | 生体吸収性高分子含有硬化型骨補填材 |
| JP2001054564A (ja) * | 1999-08-17 | 2001-02-27 | Natl Inst For Res In Inorg Mater | 生体材料 |
| WO2003011343A1 (en) * | 2001-07-27 | 2003-02-13 | National Institute Of Advanced Industrial Science And Technology | Method of regenerating bone/chondral tissues by transferring transcriptional factor gene |
| WO2003030956A2 (en) * | 2001-10-12 | 2003-04-17 | Osteotech, Inc. | Improved bone graft |
| JP2003180814A (ja) * | 2001-12-18 | 2003-07-02 | Olympus Optical Co Ltd | スキャホールド |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006167469A (ja) * | 2004-12-15 | 2006-06-29 | Heraeus Kulzer Gmbh | 作用物質を遅延放出する、単数の抗生物質/複数の抗生物質を含有する骨代用材料 |
| JP2009513197A (ja) * | 2005-10-27 | 2009-04-02 | トーメン メディカル アーゲー | 歯科インプラント及びその製造方法 |
| JP2009526614A (ja) * | 2006-02-17 | 2009-07-23 | バイオメト マニファクチャリング コーポレイション | 多孔性金属インプラントの形成方法および形成装置 |
| US8115587B2 (en) | 2008-03-28 | 2012-02-14 | Murata Manufacturing Co., Ltd. | NTC thermistor ceramic, method for producing NTC thermistor ceramic, and NTC thermistor |
| JP2010284522A (ja) * | 2009-06-12 | 2010-12-24 | Kaohsiung Medical Univ | リン酸カルシウム骨セメント、その前駆体およびその作製方法 |
| JP2011250868A (ja) * | 2010-05-31 | 2011-12-15 | Chiba Inst Of Technology | リン酸三カルシウムからなる生体材料セラミックス及びその製造方法 |
| JP2012030993A (ja) * | 2010-07-29 | 2012-02-16 | National Institute Of Advanced Industrial Science & Technology | 液相レーザー法を利用したリン酸カルシウム成膜方法 |
| JP2015509018A (ja) * | 2012-01-19 | 2015-03-26 | デピュー インターナショナル リミテッド | 骨充填剤組成物 |
| JP2016166125A (ja) * | 2015-02-27 | 2016-09-15 | 国立大学法人東北大学 | リン酸カルシウム合成装置及び合成方法 |
| JP2018528005A (ja) * | 2015-09-14 | 2018-09-27 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ (ウ・ペ・エフ・エル)Ecole Polytechnique Federale De Lausanne (Epfl) | 骨再生のための組成物 |
| JP2018531210A (ja) * | 2015-09-25 | 2018-10-25 | クリーン ワールド テクノロジーズ リミテッドClean World Technologies Ltd. | リン酸カルシウム組成物を生産すること |
| KR20180024176A (ko) * | 2016-08-29 | 2018-03-08 | 주식회사 행남생활건강 | 투광성 도자기 조성물 및 이의 제조방법 |
| KR101981065B1 (ko) * | 2016-08-29 | 2019-05-22 | 주식회사 스튜디오썸머 | 투광성 도자기 조성물 및 이의 제조방법 |
| WO2019069825A1 (ja) * | 2017-10-05 | 2019-04-11 | 国立研究開発法人産業技術総合研究所 | β-TCP基材とOCP結晶層を含む複合体及びその製造方法 |
| JP2022545185A (ja) * | 2019-08-20 | 2022-10-26 | セラダプティブ インク | 骨インプラントにおける係留可能なタンパク質の送達のための材料 |
| JP7588136B2 (ja) | 2019-08-20 | 2024-11-21 | セラダプティブ インク | 骨インプラントにおける係留可能なタンパク質の送達のための材料 |
| JPWO2021161987A1 (ja) * | 2020-02-12 | 2021-08-19 | ||
| JP7765046B2 (ja) | 2020-02-12 | 2025-11-06 | 国立研究開発法人産業技術総合研究所 | 製剤および製剤の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005032456A3 (en) | 2006-09-08 |
| US20110318402A1 (en) | 2011-12-29 |
| US8597604B2 (en) | 2013-12-03 |
| CA2535085A1 (en) | 2005-04-14 |
| US20170050849A1 (en) | 2017-02-23 |
| EP1660036A2 (en) | 2006-05-31 |
| AU2004277375A1 (en) | 2005-04-14 |
| US8029755B2 (en) | 2011-10-04 |
| US20050031704A1 (en) | 2005-02-10 |
| EP1660036A4 (en) | 2010-09-08 |
| US20140056950A1 (en) | 2014-02-27 |
| WO2005032456A2 (en) | 2005-04-14 |
| US9517293B2 (en) | 2016-12-13 |
| AU2004277375B2 (en) | 2010-12-02 |
| US10011486B2 (en) | 2018-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10011486B2 (en) | Tricalcium phosphates, their composites, implants incorporating them, and methods for their production | |
| USRE43661E1 (en) | Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production | |
| Barinov | Calcium phosphate-based ceramic and composite materials for medicine | |
| EP1545466B1 (en) | Inorganic shaped bodies and methods for their production and use | |
| Billotte | Ceramic biomaterials | |
| A Nawawi et al. | Recent progress on hydroxyapatite-based dense biomaterials for load bearing bone substitutes | |
| Ghomi et al. | Preparation of nanostructure hydroxyapatite scaffold for tissue engineering applications | |
| Ivanchenko et al. | Making calcium phosphate biomaterials | |
| TWI852918B (zh) | 骨替代材料 | |
| TWI869413B (zh) | 骨替代材料之膠原蛋白基質或顆粒摻合物及其用途 | |
| US20040019385A1 (en) | Manufacture of porous net-shaped materials comprising alpha or beta tricalcium phosphate or mixtures thereof | |
| Ameri et al. | Calcium-based triphasic powder synthesis for strengthening 3D printed bone scaffolds | |
| Chetty et al. | Synthesis, properties, and applications of hydroxyapatite | |
| Fu et al. | Calcium phosphate cements: Structure-related properties | |
| Afonina | Synthesis and characterisation of magnesium whitlockite powders via a low-temperature dissolution-precipitation process | |
| Rao | Current Trends in Processing and Shaping of Bioceramics | |
| JP2025131285A (ja) | 生体セラミックス材料およびその製造方法 | |
| HK40013259A (en) | Bone substitute material | |
| HK40013259B (en) | Bone substitute material | |
| Sadeghian | Laser sintering of hydroxyapatite by layer-wise slurry deposition (LSD) | |
| Bronzino et al. | Ceramic Biomaterials | |
| JINN | Effects of Conventional and Two-step Sintering on the Properties of Hydroxyapatite | |
| Raut et al. | Letters in Applied Na | |
| Dehsheikh | In Vitro Behavior of a Novel Nanostructure Hardystonite/Biphasic Calcium Phosphate Scaffolds (HT/BCPS); Evaluation and Investigation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110706 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120508 |